Background: In situ dying and just died tumor cells after irradiation give danger signals and release tumor-specific antigens which are sequentially incorporated into dendritic cells (DCs). Our previous studies on a murine subcutaneous tumor model showed that injection of bone marrow derived DCs (BM-DCs) after X-ray therapy significantly delayed tumor growth. As compared to X-rays, the unique biological and physical benefits of proton beam therapy may prove superior in the systemic immune effect. In addition, usage of DCs induced from iPS cells (iPS-DCs) may overcome practical problems of BM-DCs such as a limited number of applicable cells and an induction period of 7 days. The purpose of this study is to investigate: 1) whether proton beam therapy are superior in induction of anti-tumor immune response compared to X-ray therapy.
Background: Gastroesophageal adenocarcinoma (GOA) is a molecularly defined group of cancers with shared genetic alterations, poor overall survival and no routine blood based biomarker. The liquid biopsy, including circulating tumour DNA (ctDNA) is a promising technology that may improve our ability to monitor disease and enhance survival. This study aimed to determine the utility of ctDNA in GOA. Methods: A pilot study of 37 patients with GOA were recruited. These comprised 24 patients treated with curative intent and 13 palliative patients. Tumour DNA was sequenced using a custom ampliseq six gene targeted next generation sequencing (NGS) panel. Tumours from patients treated with curative intent with no detectable somatic mutation were also analysed for gene amplification via Nanostring TM nCounter. Plasma from blood samples taken at multiple time points were analysed by NGS and digital droplet PCR to detect ctDNA. Results: Somatic mutations at > 5% allele frequency were identified in 30 of 37 (81%) tumours, most commonly in TP53. Gene amplification was detected in a further three. In 11 of 13 (85%) palliative patients that had a detectable somatic mutation ctDNA was detected in 9 (82%). These ctDNA levels were dynamic, falling with treatment response and rising with disease progression, often prior to clinical relapse. 22 of 24 (92%) patients treated with curative intent had a detectable somatic mutation or gene amplification. 9 of these 22 (41%) relapsed during follow-up. CtDNA was detected prior to relapse in 7 of 22 (31%) patients and predicted poor survival (median PFS 298 vs > 1000 days, HR ¼ 11.8, p < 0.001). In 4 patients, ctDNA was detected in the postsurgical blood test, of these 3 have relapsed and one remains disease free at 5 months (median PFS 203 vs > 1000 days, HR ¼ 9.6, p ¼ 0.004). This patient will be followed up for evidence of relapse as these ctDNA positive post surgical bloods suggest detection of minimal residual disease. Conclusions: Tracking of ctDNA in patients with GOA provides valuable clinical information regarding disease progression and response, and presence of ctDNA is generally a poor prognostic sign. In addition, ctDNA may define patients with minimal residual disease who are at high risk of relapse after surgery. Legal entity responsible for the study: University of Leicester. Background: The purpose of this study is to estimate 5-year survival rates for patients with early onset breast cancer, with and without a BRCA1/2, CHEK2, NOD2 mutation or TP53 polymorphisms and to identify prognostic factors among mutation carriers in breast cancer patients. Methods: In a study conducted in the years 2007-2016 in the Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch (COI) were analyzed prognostic factors and survival in 622 breast cancer including 60 BRCA mutation carriers, 46 CHEK2 mutation carriers, 29 NOD2 mutation carriers and 87 patients with TP53 polymorphisms. Control group was selected from breast cancer patients without mutation and polymorphisms (n ¼ 400). Results: The five-year rate of OS was 75.9% for pts with BRCA mutation, 94.4% for CHEK2 mutation carriers, 96.6% for NOD2 mutation carriers and 100% for patients with TP53 polymorphisms. BRCA mutation carriers had insignificantly worse survival as compared to control group (p ¼ 0.180). Patients with CHEK2 mutation had significantly better OS than control group (p ¼ 0.032). Similarly NOD2 mutation carriers had also significantly better OS than control group (p ¼ 0.043). Patients with TP53 polymorphisms carriers had higher OS in comparison to control group (p ¼ 0.002). In subgroup of pts with N0 (Without lymph node metastases) BRCA mutation carriers was characterized by the worst OS (81.1%) among carriers of other mutations: CHEK2 (94.7%, P ¼ 0.021), NOD2 (95.3%, p ¼ 0.092) and TP53 polymorphisms (100%, p ¼ 0.007) or control group (94.4%, p ¼ 0.022). Similar tendency was observed according to Nþ subgroup and subgroup with tumor size T1-T2. Higher tumor size (HR ¼ 2.85), lymph node metastases (HR ¼ 2.93) and HER2 overexpression (HR ¼ 1.49) were significant factors for worse OS. Positive ER status was associated with a better OS (HR ¼ 0.52, p ¼ 0.001). Age <40 years (HR ¼ 0.71, p ¼ 0.255) was insignificantly favorable factor. Conclusions: CHEK2, NOD2 mutation carriers and patients with TP53 polymorphisms had better 5-year survival in comparison to patients with BRCA mutation and control group. Higher tumor size (T) and lymph node metastases (Nþ) were negative prognostic factors independently from the presence of mutations and polymorphisms. Legal entity responsible for the study: Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
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